Metabolic regulation of prostate cancer heterogeneity and plasticity

Metabolic reprogramming is one of the main hallmarks of cancer cells. It refers to the metabolic adaptations of tumor cells in response to nutrient deficiency, microenvironmental insults, and anti-cancer therapies. Metabolic transformation during tumor development plays a critical role in the contin...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in cancer biology 2022-07, Vol.82, p.94-119
Main Authors: Peitzsch, Claudia, Gorodetska, Ielizaveta, Klusa, Daria, Shi, Qihui, Alves, Tiago C., Pantel, Klaus, Dubrovska, Anna
Format: Article
Language:English
Subjects:
Cancer stem cells
Circulating tumor cells
Disseminated tumor cells
Metabolic biomarkers
Metabolic heterogeneity
Metabolic reprogramming
Metabolic therapies
Metabolomics
Prostate cancer
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metabolic reprogramming is one of the main hallmarks of cancer cells. It refers to the metabolic adaptations of tumor cells in response to nutrient deficiency, microenvironmental insults, and anti-cancer therapies. Metabolic transformation during tumor development plays a critical role in the continued tumor growth and progression and is driven by a complex interplay between the tumor mutational landscape, epigenetic modifications, and microenvironmental influences. Understanding the tumor metabolic vulnerabilities might open novel diagnostic and therapeutic approaches with the potential to improve the efficacy of current tumor treatments. Prostate cancer is a highly heterogeneous disease harboring different mutations and tumor cell phenotypes. While the increase of intra-tumor genetic and epigenetic heterogeneity is associated with tumor progression, less is known about metabolic regulation of prostate cancer cell heterogeneity and plasticity. This review summarizes the central metabolic adaptations in prostate tumors, state-of-the-art technologies for metabolic analysis, and the perspectives for metabolic targeting and diagnostic implications.
ISSN:1044-579X
1096-3650
DOI:10.1016/j.semcancer.2020.12.002